신경 혈전 제거 기기 시장 : 시장 예측(2026-2032년)

The Neurothrombectomy Devices Market is projected to grow by USD 1,281.59 million at a CAGR of 6.41% by 2032.

Neurothrombectomy Devices Executive Summary

Neurothrombectomy devices are central to modern endovascular stroke intervention, enabling rapid mechanical clot retrieval in eligible patients with acute ischemic stroke caused by large vessel occlusion. As stroke remains a leading cause of death and long-term disability worldwide, healthcare systems are prioritizing faster diagnosis, improved transfer pathways, and broader access to comprehensive stroke centers. The clinical value of stent retrievers, aspiration catheters, balloon guide catheters, distal access catheters, and integrated thrombectomy systems is closely tied to time-sensitive treatment windows, imaging-based patient selection, operator training, and post-procedure care quality.

The neurothrombectomy devices landscape is shaped by evidence-based stroke protocols, expanding use of advanced neuroimaging, and ongoing efforts to reduce delays from symptom onset to reperfusion. Demand is influenced by the rising burden of hypertension, diabetes, atrial fibrillation, aging populations, and lifestyle-related vascular risk factors, all of which are recognized contributors to ischemic stroke. At the same time, clinical adoption depends on reimbursement frameworks, regulatory approval pathways, neurointerventional workforce availability, hospital infrastructure, and emergency medical services coordination. For stakeholders, the most important growth enablers are not only device performance but also system-level readiness, including stroke network design, data-driven triage, and equitable patient access.

Transformative Shifts in the Neurothrombectomy Landscape

The neurothrombectomy devices landscape is undergoing a structural shift from isolated procedure-based adoption toward integrated stroke systems of care. Clinical practice has moved beyond simple time-based decision-making toward imaging-supported assessment of infarct core, collateral circulation, and salvageable brain tissue. This transition is strengthening the role of computed tomography angiography, computed tomography perfusion, magnetic resonance imaging, and standardized stroke scales in identifying patients who may benefit from mechanical thrombectomy.

Device innovation is also transforming procedural strategies. Larger-bore aspiration catheters, improved trackability, combined stent retriever and aspiration techniques, and refined access systems are supporting faster clot engagement and greater procedural efficiency. Hospitals are increasingly focused on first-pass reperfusion, reduced complications, and consistent performance across diverse clot types and vascular anatomies. Parallel improvements in anesthesia protocols, radial and femoral access approaches, and peri-procedural imaging are improving workflow reliability.

A second major shift is the decentralization of stroke identification through telestroke, mobile stroke units, and coordinated hub-and-spoke models. Primary stroke centers are becoming more connected to comprehensive thrombectomy-capable centers through digital image sharing, standardized transfer criteria, and pre-notification systems. This is especially important in regions with rural populations, uneven specialist distribution, and long transport times. Regulatory expectations are also becoming more rigorous, with greater emphasis on clinical evidence, device safety, post-market surveillance, and real-world performance tracking.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing neurothrombectomy workflows by accelerating large vessel occlusion detection, automating imaging interpretation, and supporting faster notification of stroke teams. AI-enabled imaging tools can assist clinicians by identifying suspected vessel occlusion, estimating ischemic core and penumbra, and prioritizing urgent cases for review. These applications are particularly relevant because treatment benefit in acute ischemic stroke is highly time-dependent, and delays in diagnosis, transfer, or angiography suite activation can affect patient outcomes.

The cumulative impact of artificial intelligence extends beyond image analysis. AI-supported clinical decision tools are being used to streamline patient routing, improve door-to-puncture coordination, and enhance communication among emergency departments, radiology teams, neurologists, and neurointerventional specialists. In stroke networks, automated alerts and cloud-based image sharing can reduce fragmentation between referring hospitals and thrombectomy centers. Over time, AI may also support quality improvement by analyzing workflow bottlenecks, reperfusion outcomes, procedural timing metrics, and complication patterns.

However, responsible deployment remains essential. AI performance must be validated across scanner types, imaging protocols, patient demographics, and regional practice settings to avoid bias and inconsistent interpretation. Clinical teams continue to require human oversight, transparent algorithms, cybersecurity safeguards, and compliance with medical device regulations. The strongest opportunity lies in using AI as an augmentation layer that improves speed, standardization, and access while preserving physician-led decision-making.

Key Regional Insights for Neurothrombectomy Devices

In North America, neurothrombectomy adoption is supported by mature stroke center certification programs, advanced emergency response systems, established reimbursement structures, and high availability of neurointerventional expertise in major urban centers. The United States has a dense network of comprehensive stroke centers and widespread use of advanced imaging for large vessel occlusion triage, while Canada emphasizes coordinated provincial stroke systems and transfer protocols to address geographic dispersion. These factors support timely mechanical thrombectomy pathways, although rural access and interfacility transport remain important operational challenges.

Europe benefits from strong clinical guideline adoption, organized stroke registries, and extensive public healthcare infrastructure. Countries across Western Europe have developed robust thrombectomy pathways, while access remains more variable across parts of Eastern and Southern Europe due to differences in workforce availability, hospital infrastructure, and cross-regional transfer efficiency. European systems increasingly prioritize quality metrics, time-to-treatment reduction, and equitable access across urban and rural populations, supported by regulatory emphasis on device safety, clinical evidence, and post-market monitoring.

Asia-Pacific presents a highly diverse environment for neurothrombectomy devices. Japan, South Korea, Australia, and parts of China have advanced stroke care capabilities, strong imaging infrastructure, and growing interventional expertise. India and Southeast Asian countries are expanding access through tertiary hospital networks, training programs, and private-sector investment, but disparities remain in emergency transport, affordability, and specialist availability. Latin America is progressing through stroke network development in countries such as Brazil and Mexico, although access to thrombectomy-capable centers is concentrated in major metropolitan areas. The Middle East is strengthening specialized stroke services through hospital modernization and regional centers of excellence, particularly in Gulf countries, while Africa faces the most significant access constraints due to limited neurointerventional infrastructure, inconsistent imaging availability, and specialized workforce distribution.

Key Group Insights Across Global Stroke Care Economies

Within the G7, neurothrombectomy device adoption is reinforced by established stroke guidelines, high procedural capacity, advanced diagnostic imaging, and broad institutional experience with endovascular therapy. These countries are also more likely to maintain national or regional stroke quality programs, enabling continuous measurement of door-to-imaging, door-to-puncture, successful reperfusion, and complication outcomes. NATO countries show similar strengths where healthcare systems are well funded and specialist stroke services are concentrated, although access levels vary considerably across member states depending on hospital distribution, public health investment, emergency transport coverage, and trained neurointerventional workforce availability.

The European Union plays a significant role in standardizing regulatory oversight, clinical safety expectations, and post-market device surveillance for neurothrombectomy devices. EU member states benefit from cross-border clinical collaboration, multicenter evidence generation, and harmonized medical device requirements, while still facing country-level differences in reimbursement, stroke center density, and workforce capacity. BRICS economies are important for future clinical expansion because they combine large stroke patient populations with increasing investment in tertiary care, imaging infrastructure, and specialist training. However, affordability, regional inequality, uneven emergency transport systems, and differences between metropolitan and non-metropolitan healthcare access continue to affect timely availability of mechanical thrombectomy.

ASEAN countries are building stroke care capacity at different speeds. Singapore and Thailand have relatively advanced tertiary stroke services, while Indonesia, Vietnam, the Philippines, and other members are working to expand imaging access, interventional training, and referral networks. The GCC is distinguished by rapid hospital modernization, strong investment in specialty care, and growing use of international clinical protocols for acute stroke management. Across NATO, G7, BRICS, the European Union, ASEAN, and GCC economies, the key differentiator is not only device availability but the maturity of the entire stroke ecosystem, from public awareness and ambulance triage to imaging, transfer, intervention, rehabilitation, and outcomes tracking.

Key Country Insights for Neurothrombectomy Devices

The United States remains one of the most advanced environments for neurothrombectomy procedures, supported by comprehensive stroke center networks, rapid imaging protocols, and extensive clinical experience in endovascular stroke therapy. Canada continues to strengthen province-led stroke systems, with a focus on addressing long-distance transfers and improving access outside major urban areas. Mexico is expanding thrombectomy capability in tertiary hospitals, though access remains uneven due to regional disparities in specialist availability, imaging infrastructure, and emergency care coordination.

Brazil has growing expertise in large urban centers and an increasing focus on organized stroke pathways, while broader access is affected by differences between public and private healthcare resources. The United Kingdom benefits from national stroke planning and centralized specialist services, with continued efforts to improve 24/7 thrombectomy availability. Germany has a highly developed stroke unit network and strong neurointerventional capacity, while France emphasizes regional coordination and guideline-based stroke care. Italy and Spain have strengthened thrombectomy access through regional stroke networks, although geographic variation persists. Russia has specialized centers in major cities, but access across vast territories depends heavily on imaging availability, referral systems, transport logistics, and interventional workforce distribution.

China is rapidly expanding stroke center infrastructure and neurointerventional training, driven by a high burden of stroke and major hospital investment. India has increasing thrombectomy adoption in metropolitan tertiary centers, with ongoing challenges related to affordability, public awareness, ambulance systems, and rural access. Japan has advanced neurointerventional expertise, strong imaging penetration, and a large aging population that reinforces the need for high-quality stroke care. Australia relies on coordinated state-based stroke networks to serve dispersed populations, while South Korea combines advanced hospital infrastructure, high imaging availability, and strong specialist capacity to support mechanical thrombectomy pathways.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-driven device development focused on procedural efficiency, vessel safety, deliverability, and performance across varied clot compositions. Product strategies should align with real-world clinical needs, including faster first-pass reperfusion, compatibility with advanced aspiration techniques, and usability in complex neurovascular anatomies. Investments in clinician education, simulation-based training, and standardized procedural workflows can improve adoption while supporting patient safety.

Stakeholders should also strengthen partnerships with hospitals, stroke networks, emergency medical services, and imaging technology providers to reduce workflow delays. Supporting integrated care pathways can be as important as device innovation because thrombectomy outcomes depend on rapid recognition, accurate triage, efficient transfer, and timely intervention. In emerging markets, organizations should consider tiered access strategies, training collaborations, and infrastructure support that address affordability and workforce constraints without compromising quality.

Regulatory and clinical teams should build robust post-market evidence programs using registries, real-world data, and long-term safety monitoring. AI integration should be pursued responsibly, with validation across diverse populations and transparent clinical governance. Commercial strategies should focus on regions where stroke system readiness is improving, while medical affairs teams should provide education on guideline alignment, patient selection, complication management, and quality improvement metrics.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified, data-backed sources relevant to neurothrombectomy devices and acute ischemic stroke care. The research framework includes review of peer-reviewed clinical literature, stroke treatment guidelines, regulatory publications, health authority documentation, hospital stroke certification criteria, public health data, and real-world evidence from stroke registries where available. Emphasis is placed on clinical adoption drivers, procedural workflow trends, regional access conditions, technology shifts, and healthcare system readiness.

The methodology applies triangulation across multiple credible source categories to ensure consistency and reduce dependence on any single data point. Clinical insights are assessed in relation to established evidence on mechanical thrombectomy for large vessel occlusion, imaging-based selection, treatment timelines, and endovascular workflow optimization. Regional and country-level interpretations are based on healthcare infrastructure, specialist availability, policy direction, stroke network maturity, and documented access challenges.

The analysis intentionally excludes market sizing, market share, and forecasting. Instead, it focuses on qualitative and evidence-aligned intelligence that supports strategic decision-making for product development, clinical adoption, regulatory planning, and regional access prioritization.

Conclusion

Neurothrombectomy devices are reshaping acute ischemic stroke treatment by enabling effective mechanical removal of large vessel occlusions when supported by timely diagnosis, appropriate patient selection, and coordinated stroke systems. The sector is advancing through device refinements, improved imaging workflows, AI-enabled triage, and broader development of thrombectomy-capable networks. While mature healthcare systems benefit from established infrastructure and specialist availability, emerging regions are building capacity through tertiary center expansion, training initiatives, and improved emergency pathways.

The most successful stakeholders will be those that view neurothrombectomy not simply as a device category but as part of a time-critical care continuum. Continued progress depends on clinical evidence, workflow integration, equitable access, responsible AI deployment, and collaboration across hospitals, emergency services, policymakers, and technology providers. As stroke systems evolve globally, neurothrombectomy devices will remain a critical component of efforts to reduce disability and improve outcomes for patients with large vessel occlusion stroke.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neurothrombectomy Devices Market, by Device Type

• 7.1. Introduction
• 7.2. Aspiration Catheters
  • 7.2.1. Intermediate Bore
  • 7.2.2. Large Bore
• 7.3. Combined Systems
  • 7.3.1. Integrated System
  • 7.3.2. Standalone Adjunct
• 7.4. Stent Retrievers
  • 7.4.1. Coated
  • 7.4.2. Uncoated

8. Neurothrombectomy Devices Market, by Procedure Type

• 8.1. Introduction
• 8.2. Aspiration Thrombectomy
• 8.3. Combined Approach
  • 8.3.1. Sequential
  • 8.3.2. Simultaneous
• 8.4. Mechanical Thrombectomy

9. Neurothrombectomy Devices Market, by Access Route

• 9.1. Introduction
• 9.2. Transfemoral Access
• 9.3. Transradial Access
• 9.4. Transbrachial Access
• 9.5. Direct Carotid Access

10. Neurothrombectomy Devices Market, by Application

• 10.1. Introduction
• 10.2. Acute Ischemic Stroke
• 10.3. Cerebral Venous Thrombosis
• 10.4. Cerebral Aneurysm Thrombosis
• 10.5. Arteriovenous Malformation (AVM) & Fistulas
• 10.6. Intracranial Occlusive Disease

11. Neurothrombectomy Devices Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Direct Sales
• 11.3. E Commerce
• 11.4. Third Party Distributor
  • 11.4.1. Independent Distributor
  • 11.4.2. Value Added Distributor

12. Neurothrombectomy Devices Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. Neurothrombectomy Devices Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. Neurothrombectomy Devices Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. India
• 14.5. Germany
• 14.6. United Kingdom
• 14.7. Australia
• 14.8. France
• 14.9. South Korea
• 14.10. Italy
• 14.11. Canada
• 14.12. Russia
• 14.13. Brazil
• 14.14. Mexico
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Acandis GmbH
• 16.2. Argon Medical Devices, Inc.
• 16.3. Imperative Care
• 16.4. iVascular S.L.U.
• 16.5. Johnson & Johnson MedTech, Inc.
• 16.6. Kaneka Corporation
• 16.7. Medtronic plc
• 16.8. Merit Medical Systems, Inc.
• 16.9. MicroPort Scientific Corporation
• 16.10. NeuroVasc Technologies, Inc.
• 16.11. Penumbra, Inc.
• 16.12. Perflow Medical Ltd.
• 16.13. Rapid Medical
• 16.14. Route 92 Medical
• 16.15. Stryker Corporation
• 16.16. Terumo Corporation
• 16.17. VESALIO
• 16.18. Wallaby Medical Holding, Inc.